Drug intelligence / Profile preview

Lactobacillus rhamnosus CCFM1138

Development stage
Preclinical
Lead developer
Hubei Juneyao Health Beverage
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Lactobacillus rhamnosus CCFM1138 is a specific strain of the probiotic bacterium *Lactobacillus rhamnosus*. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. *Lactobacillus rhamnosus* strains are commonly found in the human gastrointestinal tract and are known for their ability to survive in acidic and basic conditions, adhere to intestinal walls, and colonize the gut. They exert their beneficial effects primarily by modulating the gut microbiota, inhibiting the growth of pathogenic bacteria through the production of antimicrobial substances, and enhancing the body's immune response both locally in the gut and systemically. Additionally, they contribute to maintaining gut barrier integrity and producing short-chain fatty acids (SCFAs) that nourish colon cells. While specific detailed mechanisms and clinical data for the CCFM1138 strain are limited in publicly available information, *Lactobacillus rhamnosus* in general is associated with benefits such as improving digestive health, alleviating certain types of diarrhea, and modulating immune function. This specific strain is patented by Hubei Junyao Health Drink Co., Ltd..

Other names
鼠李糖乳杆菌CCFM1138

Beyond the preview

Go deeper on Lactobacillus rhamnosus CCFM1138.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus rhamnosus CCFM1138.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call